No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 25
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for CalciMedica, Inc. (CALC) stock was $1.54 as of Oct 5, 2026, 4:00 PM EDT, down 3.75% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -90.3% · 3-year avg -49.5%/yr
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions.
Biotechnology · La Jolla, CA
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-1.27
Revenue Est.
N/A
Last Quarter Results
EPS
$-2.25
vs Estimate
$-1.45
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1CALC | $4.85M | $1.54 | -3.75% | -90.27% | N/A | N/A | N/A |
| 2BGMS | $4.79M | $0.87 | -1.32% | -81.68% | N/A | N/A | vs CALC |
| 3BMGL | $4.96M | $3.17 | -3.35% | -83.45% | N/A | N/A | vs CALC |
| 4GELS | $4.99M | $0.54 | +4.28% | -57.02% | N/A | N/A | vs CALC |
| 5IMNN | $5.21M | $1.24 | -3.13% | -76.74% | -63.83% | -55.17% | vs CALC |
| 6DRMA | $4.46M | $1.11 | +0.45% | -77.00% | -83.90% | N/A | vs CALC |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 3 analysts
Average Price Target
$50.00
+3146.8% upside
Low
$30.00
Current
$1.54
High
$75.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-1.27 | $-1.27 | $-1.27 | 1 |
| Quarter ending Dec 2026 | $-1.05 | $-1.05 | $-1.05 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-3.02 | $-3.02 | $-3.02 | 2 |
| FY 2027 | $-5.30 | $-5.30 | $-5.30 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $2.43M | $2.43M | $2.43M | 4 |
| FY 2027 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| $6.67M |
| $6.67M |
| $6.67M |
| 3 |
